SARS-CoV-2 Omicron Antibody

<strong>SARS-CoV-2 Omicron Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2010592_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 150 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular component of various serological and antigenic assays for SARS-CoV-2 and its variants_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> SARS-CoV-2 Spike Antibody, Omicron Antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf">Download SARS-CoV-2 Brochure</a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G,_x000D_ Tambone V, Caruso A, Angeletti S, Zella D, Ciccozzi M. Evolution patterns of_x000D_ SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun. 2021_x000D_ Jan 29;538:88-91._x000D_ _x000D_ 2: Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on_x000D_ structure, pathogenicity and immunity aspects of pandemic human coronaviruses._x000D_ Infect Genet Evol. 2020 Nov;85:104502._x000D_ _x000D_ 3: Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure,_x000D_ Biology, and Structure-Based Therapeutics Development. Front Cell Infect_x000D_ Microbiol. 2020 Nov 25;10:587269._x000D_ _x000D_ 4: Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and_x000D_ Pathogenesis. Trends Immunol. 2020 Dec;41(12):1100-1115._x000D_ _x000D_ 5: Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat_x000D_ Rev Microbiol. 2021 Mar;19(3):141-154._x000D_ _x000D_ 6: Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-_x000D_ Ronen Y, Tamir H, Achdout H, Stein D, Israeli O, Beth-Din A, Melamed S, Weiss S,_x000D_ Israely T, Paran N, Schwartz M, Stern-Ginossar N. The coding capacity of SARS-_x000D_ CoV-2. Nature. 2021 Jan;589(7840):125-130._x000D_ _x000D_ 7: Bakhiet M, Taurin S. SARS-CoV-2: Targeted managements and vaccine_x000D_ development. Cytokine Growth Factor Rev. 2021 Apr;58:16-29._x000D_ _x000D_ 8: Sanyal S. How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we_x000D_ know so far. Emerg Top Life Sci. 2020 Dec 11;4(4):371-378._x000D_ _x000D_ 9: Campos DMO, Fulco UL, de Oliveira CBS, Oliveira JIN. SARS-CoV-2 virus_x000D_ infection: Targets and antiviral pharmacological strategies. J Evid Based Med._x000D_ 2020 Nov;13(4):255-260._x000D_ _x000D_ 10: Peng L, Liu J, Xu W, Luo Q, Chen D, Lei Z, Huang Z, Li X, Deng K, Lin B, Gao_x000D_ Z. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal_x000D_ swabs specimens. J Med Virol. 2020 Sep;92(9):1676-1680._x000D_ _x000D_ 11: Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a_x000D_ global pandemic: Understanding the epidemiology, immune response and potential_x000D_ therapeutic targets of SARS-CoV-2. Biochimie. 2020 Dec;179:85-100._x000D_ _x000D_ 12: Yang Q, Hughes TA, Kelkar A, Yu X, Cheng K, Park S, Huang WC, Lovell JF,_x000D_ Neelamegham S. Inhibition of SARS-CoV-2 viral entry upon blocking N- and_x000D_ O-glycan elaboration. Elife. 2020 Oct 26;9:e61552._x000D_ _x000D_ 13: Rahbari R, Moradi N, Abdi M. rRT-PCR for SARS-CoV-2: Analytical_x000D_ considerations. Clin Chim Acta. 2021 May;516:1-7._x000D_ _x000D_ 14: Zapor M. Persistent Detection and Infectious Potential of SARS-CoV-2 Virus_x000D_ in Clinical Specimens from COVID-19 Patients. Viruses. 2020 Dec 3;12(12):1384._x000D_ _x000D_ 15: Gao J, Quan L. Current Status of Diagnostic Testing for SARS-CoV-2 Infection_x000D_ and Future Developments: A Review. Med Sci Monit. 2020 Dec 17;26:e928552._x000D_ _x000D_ 16: Flower TG, Buffalo CZ, Hooy RM, Allaire M, Ren X, Hurley JH. Structure of_x000D_ SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein. Proc Natl Acad Sci U_x000D_ S A. 2021 Jan 12;118(2):e2021785118._x000D_ _x000D_ 17: Hossain MG, Javed A, Akter S, Saha S. SARS-CoV-2 host diversity: An update_x000D_ of natural infections and experimental evidence. J Microbiol Immunol Infect._x000D_ 2021 Apr;54(2):175-181._x000D_ _x000D_ 18: Boretti A. Favipiravir use for SARS CoV-2 infection. Pharmacol Rep. 2020_x000D_ Dec;72(6):1542-1552._x000D_ _x000D_ 19: Awadasseid A, Wu Y, Tanaka Y, Zhang W. SARS-CoV-2 variants evolved during_x000D_ the early stage of the pandemic and effects of mutations on adaptation in Wuhan_x000D_ populations. Int J Biol Sci. 2021 Jan 1;17(1):97-106._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33031947/">20: Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, Wang S, Deng G, Zhou H, Wu Y._x000D_ Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-_x000D_ CoV-2 infection. Clin Microbiol Infect. 2021 Feb;27(2):289.e1-289.e4. </a>_x000D_ _x000D_ <strong>Products Related to SARS-CoV-2 Omicron Antibody</strong><a href="https://moleculardepot.com/product-category/Antibodies/">: Antibodies</a>